within Pharmacolibrary.Drugs.ATC.C;

model C04AC02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.0004166666666666667,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C04AC02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nicotinyl alcohol, also known as pyridylcarbinol, is a vasodilator belonging to the nicotinic acid derivatives. It was historically used for the treatment of peripheral vascular diseases such as Raynaud's disease and arteriosclerosis, but is generally not in widespread clinical use today with modern alternatives available.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic parameters are reported in the published literature in humans or animals according to available sources. Model estimates are provided here for adult oral administration based on general properties of small, hydrophilic, nicotinic-acid related molecules.</p><h4>References</h4><ol><li><p>Cheymol, G, et al., &amp; Poitou, P (1984). [Blood pharmacokinetics of fluorine in man after the oral administration of nicomethanol hydrofluoride]. <i>Journal de biologie buccale</i> 12(4) 349–353. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6597190/&quot;>https://pubmed.ncbi.nlm.nih.gov/6597190</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C04AC02;
